TherVacB – A therapeutic vaccine to cure hepatitis B

Novel therapeutic vaccine to cure hepatitis B

Spontaneous resolution of hepatitis b virus (HBV) infection is characterised by neutralising antibodies and HBV-specific T cell responses, elements which are lacking in chronic HBV infection. The EU-funded TherVacB project aims to overcome immune tolerance in chronic HBV infection and the virus’s resistance to cure. The interdisciplinary consortium will employ a heterologous prime-boost therapeutic vaccination scheme with proven efficacy in preclinical models of hepatitis B to target and activate B and T cell responses; thereby, TherVacB hopes to produce vaccine components and prepare a first-in-human application. To provide a clinical proof of concept of the therapeutic hepatitis B vaccine in patients with chronic hepatitis B, the consortium will establish a patient registry and perform a multicentre phase Ib/IIa clinical trial of the vaccine's safety and potency to induce immune control of chronic HBV infection.



Supported by BayFOR:

Research Focus:

  • Medicine and Health

Project Coordination:

Helmholtz Munich

Project Partner:

ARTTIC Innovation GmbH
Ludwig-Maximilians-Universität Munich
National Institute for Medical Research Tanzania
NIMR – National Insitute for Medical Research
Rechts der Isar Hospital (Technical University of Munich)
Technical University of Munich


Tanzania, United Republic Of, Germany (Bavaria)

Funding Agency:

European Union

Funding Type:



- 31/12/2024